EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell

Ye Yang, Shuo Liu, Yufeng Luo, Bolun Wang, Junyi Wang, Juan Li, Jiaxin Li, Buqing Ye, Youchun Wang, Jianzhong Jeff Xi

PLOS Pathogens · 2023

DOI: 10.1371/journal.ppat.1011119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Ye Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing,…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Basic Research Project of China, National Natural Science Foundation of China, PKU-Baidu Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As new mutations continue to emerge, the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to evade the human immune system and neutralizing antibodies remains a huge challenge for vaccine development and antibody research. The majority of neutralizing antibodies have reduced or lost activity against SARS-CoV-2 variants. In this study, we reported a novel protein surface display system on a mammalian cell for obtaining a higher-affinity antibody in high-throughput manner. Using a saturation mutagenesis strategy through integrating microarray-based oligonucleotide synthesis and single-cell screening assay, we generated a group of new antibodies against diverse prevalent SARS-CoV-2 variants through high-throughput screening the human antibody REGN10987 within 2 weeks. The affinity of those optimized antibodies to seven prevalent mutants was greatly improved, and the EC50 values were no higher than 5 ng/mL. These results demonstrate the robustness of our screening system in the rapid generation of an antibody with higher affinity against a new SARS-CoV-2 variant, and provides a potential application to other protein molecular interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19AnimalsHumansMutagenesisMembrane ProteinsAntibodies, NeutralizingSpike Glycoprotein, CoronavirusAntibodies, ViralMammals

Substanzen

Membrane ProteinsAntibodies, NeutralizingSpike Glycoprotein, CoronavirusAntibodies, Viralspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
  • Graduate School of Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China.

Förderung

  • National Key Basic Research Project of China
  • National Natural Science Foundation of China
  • PKU-Baidu Fund
  • Beijing Municipal Science and Technology Project

Zitieren

APA

Yang, Y., Liu, S., Luo, Y., Wang, B., Wang, J., Li, J., Li, J., Ye, B., Wang, Y., & Xi, J. J. (2023). High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011119

Vancouver

Yang Y, Liu S, Luo Y, Wang B, Wang J, Li J, et al. High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011119

BibTeX
@article{Yang2023,
  author = {Yang, Ye and Liu, Shuo and Luo, Yufeng and Wang, Bolun and Wang, Junyi and Li, Juan and Li, Jiaxin and Ye, Buqing and Wang, Youchun and Xi, Jianzhong Jeff},
  title = {High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell},
  journal = {PLOS Pathogens},
  year = {2023},
  doi = {10.1371/journal.ppat.1011119}
}
Kostenlos starten →